CRL News & Events

Charles River Laboratories and Medipost have entered into a strategic, non-exclusive Memorandum of Understanding to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River's expertise in biologics and cell therapy GMP testing to support Medipost's global cell therapy pipeline, starting in the Asia-Pacific and North America regions, with possible expansion into Middle East and Europe. "We are excited to deepen our partnership with MEDIPOST and collaborate with a top global cell therapy developer, assisting at both clinical and commercialization phases," said Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River. "By collaborating with industry leaders, we aim to expand GMP testing capabilities and help ensure that safe, compliant products reach patients more efficiently."

Charles River Laboratories International announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate. By fully integrating digital pathology across the histology and pathology workflow, Charles River is committed to cutting at least one week from standard pathology timelines while maintaining Good Laboratory Practice rigor and regulatory readiness. These efficiency gains are driven by the combination of a fully integrated histology laboratory information management system, AI-powered slide quality control, and validated digital primary pathology reviews.